Serum concentration of lignocaine after pertubation: an observational study

Karin Wickström, Jack Spira, Greta Edelstam, Karin Wickström, Jack Spira, Greta Edelstam

Abstract

Objective: The objective of this study was to report the serum concentration of lignocaine after pertubation in patients with endometriosis.

Design: Prospective observational study.

Setting: The study was carried out at a gynaecological outpatient unit in Stockholm, Sweden.

Population: Eligible patients had endometriosis with a dysmenorrhoic pain score of >50 mm on a visual analogue scale, and patent fallopian tubes.

Methods: Patients with endometriosis (n = 25) were included in the study. The patients received pre-ovulatory pertubations with lignocaine hydrochloride 10 mg (n = 16) or ringer acetate (placebo, n = 9). The procedure comprised passing the study solution through the uterus and the fallopian tubes via an intra-cervical balloon catheter. Serum samples were collected at 0, 5, 15 and 30 min after pertubation.

Main outcome measures: The serum samples were analysed for the concentration of lignocaine with an LCMS-SIM method.

Results: Low levels of lignocaine were detected in the serum samples following pertubation of 10 mg lignocaine hydrochloride. The highest observed concentration was seen after 30 min (mean 0.050 μg/ml), with an individual maximum of 0.124 μg/ml. Maximum concentration (C max) and time to C max (T max) could not be calculated, since the highest values were observed in the 30-min samples, which was the last sample obtained. Lignocaine was not detected after pertubation with placebo.

Conclusions: The serum levels of lignocaine following pertubation of 10 mg lignocaine hydrochloride are detectable but low. Lignocaine pertubated through the fallopian tubes reaches the peritoneal cavity and diffuses through the peritoneum into the blood circulation. Pertubation with lignocaine is safe and has no lignocaine-related adverse events.

Trial registration: ClinicalTrials.gov NCT01329796.

Figures

Fig. 1
Fig. 1
Serum concentration of lignocaine

References

    1. Cambridge GW, Parsons JF, Friend JV, Jones PA. Some effects of lignocaine on cultured mouse peritoneal macrophages. Agents Actions. 1985;16(6):548–551. doi: 10.1007/BF01983661.
    1. Hollman MW, Durieux ME. Local anesthetics and the inflammatory response. Anesthesiology. 2000;93(3):858–875. doi: 10.1097/00000542-200009000-00038.
    1. Agic A, Xu H, Finas D, Banz C, Diedrich K, Hornung D. Is endometriosis associated with systemic subclinical inflammation? Gynecol Obstet Invest. 2006;62(3):139–147. doi: 10.1159/000093121.
    1. Berkley KJ, Rapkin AJ, Papka RE. The pains of endometriosis. Science. 2005;308(5728):1587–1589. doi: 10.1126/science.1111445.
    1. Christodoulakos G, Augoulea A, Lambrinoudaki I, Sioulas V, Creatsas G. Pathogenesis of endometriosis: the role of defective ‘immunosurveillance’. Eur J Contracept Reprod Health Care. 2007;12(3):194–202. doi: 10.1080/13625180701387266.
    1. Medina MG, Lebovic DI. Endometriosis-associated nerve fibers and pain. Acta Obstet Gynecol Scand. 2009;88(9):968–975. doi: 10.1080/00016340903176826.
    1. Edelstam GAB, Sjösten ACE, Salamon CW. Pertubation with lignocaine-a possible new treatment for women with endometriosis and impaired fertility. Ups J Med Sci. 2001;106:51–58. doi: 10.3109/2000-1967-172.
    1. Edelstam G, Sjösten A, Jablonowska B, Kjellberg S, Spira J. Pertubation with lidocaine—a non-hormonal, long-term treatment of dysmenorrhea due to endometriosis. Sex Reprod Healthc. 2012;3(2):93–4.
    1. Edelstam G, Sjösten A, Bjuresten K, Ek I, Wånggren K, Spira J. A new rapid and effective method for treatment of unexplained infertility. Hum Reprod. 2008;23(4):852–6.
    1. Yagiela JH. Local anesthetics. Anesth Prog. 1991;38:128–141.
    1. Kahokehr A, Sammour T, Vather R, Taylor M, Stapelberg F, Hill AG. Systemic levels of local anaesthetic after intra-peritoneal application–a systematic review. Anaesth Intensive Care. 2010;38(4):623–638.
    1. Benowitz NL, Meister W. Clinical pharmacokinetics of lignocaine. Clin Pharmacokinet. 1978;3:177–201.
    1. Oral E, Olive DL, Arici A. The peritoneal environment in endometriosis. Hum Reprod Update. 1996;2(5):385–398. doi: 10.1093/humupd/2.5.385.
    1. DiZerega GS, Rodgers KE. The peritoneum. New York: Springer; 1992.
    1. Koninckx PR, Kennedy SH, Barlow DH. Endometriotic disease: the role of peritoneal fluid. Hum Reprod Update. 1998;4(5):741–751. doi: 10.1093/humupd/4.5.741.
    1. Narchi P, Benhamou D, Bouaziz H, Fernandez H, Mazoit JX. Serum concentrations of local anaesthetics following intraperitoneal administration during laparoscopy. Eur J Clin Pharmacol. 1992;42:223–225. doi: 10.1007/BF00278490.
    1. Wickström K, Bruse C, Sjösten A, Spira J, Edelstam G. Pertubation with lignocaine as a new treatment of dysmenorrhea due to endometriosis: a randomized controlled trial. Hum Reprod. 2012;27(3):695–701. doi: 10.1093/humrep/der434.
    1. Masse RI, Dunbar RW. Plasma lidocaine concentrations after caudal, lumbar, epidural, axillary block, and intravenous regional anesthesia. Anesthesiology. 1966;27(3):574–579.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅